Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyCALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy with or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer

This study reports long term outcomes on CALGB 40603 at a median follow-up of 7.9 years. Event-free survival and other LTOs were not significantly improved with either study drug overall or in studied sub-populations. Results showed that patients with any residual disease had significantly worse outcomes. This finding supports considering adjuvant therapy even in the setting of minimal residual disease.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form